205117-47-1

Basic information

• Product Name: Bifendate Impurity E
• Synonyms: Bifendate Impurity E;Bifendate Impurity 7;7,7'-dimethoxy-5'-(methoxycarbonyl)-[4,4'-bibenzo[d][1,3]dioxole]-5-carboxylic acid;Bicyclol Impurity D;Bifendate Impurity
• CAS NO: 205117-47-1
• Molecular Formula: C₁₉H₁₆O₁₀
• Molecular Weight: 404.32434
• Mol File: 205117-47-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Bifendate Impurity E(CAS DataBase Reference)
• NIST Chemistry Reference: Bifendate Impurity E(205117-47-1)
• EPA Substance Registry System: Bifendate Impurity E(205117-47-1)

Safety Data

• Hazardous Substances Data: 205117-47-1(Hazardous Substances Data)

Usage

Uses

7,7''-Dimethoxy-[4,4''-Bi-1,3-benzodioxole]-5,5''-dicarboxylic Acid Monomethyl Ester, is an impurity of Bifendate (B382890), a synthetic intermediate of Schisandrin C and also a anti-HBV drug used in the treatment of chronic hepatitis B.

Upstream product

• 67-56-1 methanol 
• 111897-21-3 dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylic acid 
• 111897-19-9 DDB 

Downstream Products

• 1350363-27-7 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-ethoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-28-8 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-29-9 (E)-5-(3-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-30-2 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2,6-dimethoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-31-3 (E)-5-(2,4-dichloro-6-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-32-4 (Z)-5-(2-bromo-4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-33-5 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-fluorophenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-34-6 (E)-5-(2,4-dibromo-6-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-35-7 (E)-5-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-36-8 (E)-5-(2-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-37-9 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-38-0 (E)-5-(4-chloro-2-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-25-5 5-(4-formylphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-26-6 5-(4-chloro-2-formylphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo-[d][1,3]dioxole-5,5'-dicarboxylate 

Relevant articles and documents

Alkoxybiphenyl alpha, beta-unsaturated amide compound and preparing method and medical application thereof

The invention relates to an alkoxybiphenyl alpha, beta-unsaturated amide compound and a preparing method and medical application thereof, and belongs to the fields of medicinal chemistry and pharmacotherapeutics. The invention provides application of the compound shown in the formula I or pharmaceutically acceptable salt thereof in preparing drugs for antioxidation related diseases, especially theapplication in preparing anti-inflammatory drugs or antioxidant drugs. (The formula is shown in the description.).

Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents

A series of substituted dibenzo[c,e]azepine-5-ones (7a-h) were synthesized and evaluated as P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) reversal agents. The most potent compound 7h could significantly and selectively enhance the chemo-sensit

Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors

Overexpression of P-glycoprotein (P-gp) is one of the major problems to successful cancer chemotherapy. To find novel effective P-gp inhibitors, a series of bifendate-chalcone hybrids were synthesized and evaluated. Among them, the most active compound 8g